Review Article

Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery

Author(s):

Harmeet Kaur, Sapna D. Desai, Virender Kumar, Pooja Rathi and Jasbir Singh   Pages 1355 - 1377 ( 23 )

Abstract:

New polymer therapeutics like polymer-drug conjugates (PDCs) are developing day by day. Heterocyclic drugs with excellent cytotoxic properties are available, but lack of their specificity makes them available to the normal cells also, which is the main cause of their toxicity. Drugs in the form of PDCs make delivery possible to the specific sites. Most of the PDCs are designed with the aim to either target and/or to get activated in specific cancer microenvironments. Therefore, the most exploited targets for cancer drug delivery are; cancer cell enzymes, heat shock protein 90 (HSP90), multi-drug resistance (MDR) proteins, angiogenesis, apoptosis and cell membrane receptors (e.g., folates, transferrin, etc.). In this review, we will summarize PDCs of heterocyclic drugs, like doxorubicin (DOX), daunorubicin, paclitaxel (PTX), docetaxel (DTX), cisplatin, camptothecin (CPT), geldanamycin (GDM), etc., and some of their analogs for efficient delivery of drugs to cancer cells.

Keywords:

Cancer, targeting, endocytosis, angiogenesis, apoptosis, ligand, dendrimer, micelles, block copolymers.

Affiliation:

, , , , College of Pharmacy, University of Health Sciences, Rohtak-124001, India.

Graphical Abstract:

Read Full-Text article